Royal Bank of Canada’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2K | Sell |
1,368
-1,385
| -50% | -$6.07K | ﹤0.01% | 6660 |
|
|
2025
Q4 | $15K | Sell |
2,753
-51,573
| -95% | -$265K | ﹤0.01% | 6186 |
|
|
2025
Q3 | $284K | Sell |
54,326
-65,816
| -55% | -$343K | ﹤0.01% | 4867 |
|
|
2025
Q2 | $460K | Buy |
120,142
+116,708
| +3,399% | +$302K | ﹤0.01% | 4533 |
|
|
2025
Q1 | $19K | Sell |
3,434
-3,771
| -52% | -$22.3K | ﹤0.01% | 5932 |
|
|
2024
Q4 | $36K | Buy |
7,205
+2,334
| +48% | +$12K | ﹤0.01% | 5847 |
|
|
2024
Q3 | $27K | Buy |
4,871
+185
| +4% | +$881 | ﹤0.01% | 5988 |
|
|
2024
Q2 | $16K | Buy |
4,686
+3,641
| +348% | +$14.3K | ﹤0.01% | 6144 |
|
|
2024
Q1 | $3K | Sell |
1,045
-13,405
| -93% | -$44.1K | ﹤0.01% | 6563 |
|
|
2023
Q4 | $51K | Buy |
14,450
+8,609
| +147% | +$26.6K | ﹤0.01% | 5979 |
|
|
2023
Q3 | $39K | Buy |
5,841
+2,940
| +101% | +$21.8K | ﹤0.01% | 5901 |
|
|
2023
Q2 | $24K | Buy |
2,901
+2,526
| +674% | +$24.9K | ﹤0.01% | 6109 |
|
|
2023
Q1 | $4K | Sell |
375
-1,737
| -82% | -$12.3K | ﹤0.01% | 6604 |
|
|
2022
Q4 | $15K | Sell |
2,112
-140
| -6% | -$800 | ﹤0.01% | 6397 |
|
|
2022
Q3 | $12K | Buy |
2,252
+1,289
| +134% | +$7.73K | ﹤0.01% | 6329 |
|
|
2022
Q2 | $4K | Sell |
963
-2,045
| -68% | -$7.03K | ﹤0.01% | 6699 |
|
|
2022
Q1 | $13K | Sell |
3,008
-7,549
| -72% | -$30.1K | ﹤0.01% | 6823 |
|
|
2021
Q4 | $42K | Buy |
10,557
+5,997
| +132% | +$45.7K | ﹤0.01% | 6464 |
|
|
2021
Q3 | $40K | Buy |
4,560
+742
| +19% | +$6.81K | ﹤0.01% | 6286 |
|
|
2021
Q2 | $44K | Buy |
3,818
+986
| +35% | +$11.9K | ﹤0.01% | 6118 |
|
|
2021
Q1 | $34K | Buy |
2,832
+292
| +11% | +$3.36K | ﹤0.01% | 6117 |
|
|
2020
Q4 | $17K | Hold |
2,540
| – | – | ﹤0.01% | 6126 |
|
|
2020
Q3 | $19K | Sell |
2,540
-1,682
| -40% | -$10.9K | ﹤0.01% | 5709 |
|
|
2020
Q2 | $17K | Buy |
4,222
+911
| +28% | +$3.33K | ﹤0.01% | 5644 |
|
|
2020
Q1 | $8K | Sell |
3,311
-791
| -19% | -$3.56K | ﹤0.01% | 5883 |
|
|
2019
Q4 | $24K | Buy |
4,102
+4,009
| +4,311% | +$23.2K | ﹤0.01% | 5775 |
|
|
2019
Q3 | $0 | Buy |
93
+53
| +133% | +$285 | ﹤0.01% | 6660 |
|
|
2019
Q2 | $0 | Hold |
40
| – | – | ﹤0.01% | 6829 |
|
|
2019
Q1 | $0 | Hold |
40
| – | – | ﹤0.01% | 6770 |
|
|
2018
Q4 | $0 | Sell |
40
-262
| -87% | -$2.69K | ﹤0.01% | 6701 |
|
|
2018
Q3 | $5K | Buy |
302
+80
| +36% | +$649 | ﹤0.01% | 6244 |
|
|
2018
Q2 | $1K | Buy |
222
+182
| +455% | +$1.45K | ﹤0.01% | 6325 |
|
|
2018
Q1 | $0 | Sell |
40
-24
| -38% | -$182 | ﹤0.01% | 6300 |
|
|
2017
Q4 | $0 | Buy |
64
+55
| +611% | +$362 | ﹤0.01% | 6500 |
|
|
2017
Q3 | $0 | Buy |
9
+8
| +800% | +$42 | ﹤0.01% | 6677 |
|
|
2017
Q2 | $0 | Buy |
+1
| New | +$5 | ﹤0.01% | 6538 |
|
Other funds holding ALDX
KCM
VCM
KCM
6CM
Royal Bank of Canada's ALDX Position: Q1 2026 in Review
Royal Bank of Canada reduced its Aldeyra Therapeutics (ALDX) stake by 50% in Q1 2026, selling an estimated $6.07K and leaving 1,368 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6660.
Royal Bank of Canada first reported a position in ALDX in Q2 2017 and has held it in 36 quarters since. The position peaked at $460K in Q2 2025. 127 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.
- Royal Bank of Canada held 1,368 shares of Aldeyra Therapeutics worth $2K as of Q1 2026.
- Royal Bank of Canada sold 1,385 Aldeyra Therapeutics shares in Q1 2026, an estimated $6.07K.
- Aldeyra Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6660 holding.
- Royal Bank of Canada first reported a position in Aldeyra Therapeutics in Q2 2017 and has held it in 36 quarters since.
- Royal Bank of Canada's Aldeyra Therapeutics position peaked at $460K in Q2 2025.
- 127 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.